A 32-year-old man developed gastroparesis after taking tirzepatide for weight loss, which isn't approved in India. Doctors ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...

Angie from Milwaukee Medical Weight Loss & Medispa is here today to chat about how weight loss injectables are a game changer for people and her practice.

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Fortunately, so much research has come out about diabetes and weight-loss drugs like Ozempic and Wegovy that we know ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Meanwhile, tirzepatide – the active ingredient in Eli Lilly's weight loss shot Zepbound and diabetes drug Mounjaro –mimics two hunger-regulating hormones, GLP-1 and GIP. Novo Nordisk's weight ...